Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Blood ; 129(7): 906-916, 2017 02 16.
Artigo em Inglês | MEDLINE | ID: mdl-28057639

RESUMO

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Lymphocyte trafficking via chemokine receptors such as CCR5 plays a critical role in alloreactive responses, and previous data suggest that CCR5 blockade with maraviroc results in a low incidence of visceral GVHD. However, the full scope of clinical and immunologic effects of CCR5 blockade in HSCT has not been described. We compared a cohort of patients enrolled on a trial of reduced-intensity allo-HSCT with standard GVHD prophylaxis plus maraviroc to a contemporary control cohort receiving standard GVHD prophylaxis alone. Maraviroc treatment was associated with a lower incidence of acute GVHD without increased risk of disease relapse, as well as reduced levels of gut-specific markers. At day 30, maraviroc treatment increased CCR5 expression on T cells and dampened T-cell activation in peripheral blood without impairing early immune reconstitution or increasing risk for infections. Patients who developed acute GVHD despite maraviroc prophylaxis showed increased T-cell activation, naive T-cell skewing, and elevated serum CXCL9 and CXCL10 levels. Collectively, these data suggest that maraviroc effectively protects against GVHD by modulating alloreactive donor T-cell responses, and that CXCR3 signaling may be an important resistance mechanism to CCR5 blockade in GVHD.


Assuntos
Antagonistas dos Receptores CCR5/uso terapêutico , Doença Enxerto-Hospedeiro/prevenção & controle , Transplante de Células-Tronco Hematopoéticas/métodos , Ativação Linfocitária/efeitos dos fármacos , Receptores CCR5/imunologia , Linfócitos T/efeitos dos fármacos , Adulto , Idoso , Antígenos de Neoplasias/análise , Antígenos de Neoplasias/imunologia , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/imunologia , Feminino , Doença Enxerto-Hospedeiro/imunologia , Doença Enxerto-Hospedeiro/patologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Imunidade Celular/efeitos dos fármacos , Interleucina-15/análise , Interleucina-15/imunologia , Lectinas Tipo C/análise , Lectinas Tipo C/imunologia , Masculino , Pessoa de Meia-Idade , Proteínas Associadas a Pancreatite , Linfócitos T/imunologia , Linfócitos T/patologia , Transplante Homólogo , Resultado do Tratamento , Adulto Jovem
2.
Biochemistry ; 51(31): 6148-63, 2012 Aug 07.
Artigo em Inglês | MEDLINE | ID: mdl-22788966

RESUMO

Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyzes the first unique step of the GMP branch of the purine nucleotide biosynthetic pathway. This enzyme is found in organisms of all three kingdoms. IMPDH inhibitors have broad clinical applications in cancer treatment, as antiviral drugs and as immunosuppressants, and have also displayed antibiotic activity. We have determined three crystal structures of Bacillus anthracis IMPDH, in a phosphate ion-bound (termed "apo") form and in complex with its substrate, inosine 5'-monophosphate (IMP), and product, xanthosine 5'-monophosphate (XMP). This is the first example of a bacterial IMPDH in more than one state from the same organism. Furthermore, for the first time for a prokaryotic enzyme, the entire active site flap, containing the conserved Arg-Tyr dyad, is clearly visible in the structure of the apoenzyme. Kinetic parameters for the enzymatic reaction were also determined, and the inhibitory effect of XMP and mycophenolic acid (MPA) has been studied. In addition, the inhibitory potential of two known Cryptosporidium parvum IMPDH inhibitors was examined for the B. anthracis enzyme and compared with those of three bacterial IMPDHs from Campylobacter jejuni, Clostridium perfringens, and Vibrio cholerae. The structures contribute to the characterization of the active site and design of inhibitors that specifically target B. anthracis and other microbial IMPDH enzymes.


Assuntos
Bacillus anthracis/enzimologia , IMP Desidrogenase/química , IMP Desidrogenase/metabolismo , Inosina Monofosfato/metabolismo , Ribonucleotídeos/metabolismo , Sequência de Aminoácidos , Apoenzimas/antagonistas & inibidores , Apoenzimas/química , Apoenzimas/metabolismo , Benzimidazóis/química , Benzimidazóis/metabolismo , Benzimidazóis/farmacologia , Domínio Catalítico , Inibidores Enzimáticos/química , Inibidores Enzimáticos/metabolismo , Inibidores Enzimáticos/farmacologia , IMP Desidrogenase/antagonistas & inibidores , Modelos Moleculares , Dados de Sequência Molecular , Ácido Micofenólico/metabolismo , NAD/metabolismo , Ligação Proteica , Triazóis/química , Triazóis/metabolismo , Triazóis/farmacologia , Xantina
3.
Transplant Cell Ther ; 28(1): 18.e1-18.e10, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34597852

RESUMO

Vitamin D promotes a shift from a proinflammatory to a more tolerogenic immune state in allogeneic hematopoietic cell transplant (HCT) recipients. The dominant mechanism responsible for this shift has not been elucidated. We took a multifaceted approach to evaluating the clinical and immunologic impact of low vitamin D levels in 53 HCT recipients. We used 28-plex flow cytometry for immunophenotyping, serum cytokine levels, T-cell cytokine production, and T-cell whole genome transcription. The median day-30 vitamin D level was 20 ng/mL, and deficiency was common in younger patients undergoing myeloablative transplantation. Low vitamin D levels were associated with a high CD8/Treg ratio, increased serum levels and T-cell production of proinflammatory cytokines, and a gene expression signature of unrestrained T-cell proliferation and epigenetic modulation through the PRC2/EZH2 complex. Immunophenotyping confirmed a strong association between high levels of vitamin D and an activated EZH2 signature, characterized by overexpression of ID3, which has a role in effector T-cell differentiation. Our findings demonstrate the critical role of vitamin D in modulating T-cell function in human GVHD and identify a previously undescribed interaction with EZH2 and ID3, which may impact effector differentiation and has implications to cell therapies and other forms of cancer immunotherapy. © 20XX American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.


Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Deficiência de Vitamina D , Proteína Potenciadora do Homólogo 2 de Zeste/genética , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Proteínas Inibidoras de Diferenciação , Proteínas de Neoplasias , Condicionamento Pré-Transplante , Transplante Homólogo
4.
PLoS One ; 11(1): e0147013, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26751383

RESUMO

Women exposed to phthalates during pregnancy are at increased risk for delivering preterm, but the mechanism behind this relationship is unknown. Placental corticotropin-releasing hormone (CRH) and cyclooxygenase-2 (COX-2) are key mediators of parturition and are regulated by the non-canonical NF-kB (RelB/p52) signaling pathway. In this study, we demonstrate that one of the major phthalate metabolites, mono-(2-ethylhexyl)-phthalate (MEHP), increased CRH and COX-2 mRNA and protein abundance in a dose-dependent manner in primary cultures of cytotrophoblast. This was coupled with an increase in nuclear import of RelB/p52 and its association with the CRH and COX-2 promoters. Silencing of NF-kB inducing kinase, a central signaling component of the non-canonical NF-kB pathway, blocked MEHP-induced upregulation of CRH and COX-2. These results suggest a potential mechanism mediated by RelB/p52 by which phthalates could prematurely induce pro-labor gene activity and lead to preterm birth.


Assuntos
Regulação da Expressão Gênica , Trabalho de Parto/genética , Trabalho de Parto/metabolismo , Ácidos Ftálicos/metabolismo , Placenta/metabolismo , Núcleo Celular/metabolismo , Cesárea , Hormônio Liberador da Corticotropina/genética , Hormônio Liberador da Corticotropina/metabolismo , Ciclo-Oxigenase 2/genética , Ciclo-Oxigenase 2/metabolismo , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Técnicas de Silenciamento de Genes , Humanos , NF-kappa B/metabolismo , Ácidos Ftálicos/farmacologia , Placenta/efeitos dos fármacos , Gravidez , Ligação Proteica , Proteínas Serina-Treonina Quinases/genética , Transporte Proteico , Fator de Transcrição RelB/metabolismo , Trofoblastos/metabolismo , Regulação para Cima , Quinase Induzida por NF-kappaB
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA